AstraZeneca’s new FluMist Home marks the first FDA-approved influenza vaccine available for self- or caregiver administration at home.
It’s a pivotal shift: patients are completing the entire care journey, including eligibility, prescribing, fulfillment, and administration, without ever entering a clinic.
While vaccines are relatively straightforward, this model raises important questions for specialty therapies:
- How do we balance convenience with safety monitoring?
- What systems are needed to verify benefits, manage affordability, and document compliance?
- How can we design programs that are flexible enough to evolve, but rigorous enough to withstand scrutiny?
For those of us in patient services, the launch of FluMist Home isn’t just a milestone in preventive care. It’s a signal of the broader transformation already underway that will require manufacturers to think differently about hub models, technology integration, and patient-centered design.
The future of access won’t be defined by a single innovation. It will be defined by how quickly we adapt.
— Mary Lynn Kelley
President, eMAX Health Patient Services